Abstract
Echinocandins are approved for the treatment of candidal infections. In vitro they have been shown to be less potent against strains of Candida parapsilosis than against other Candida spp. This is the first case report describing the development of a secondary multidrug (echinocandin-azole)-resistant Candida strain during therapy.
MeSH terms
-
Antifungal Agents / pharmacology*
-
Azoles / pharmacology*
-
Candida / drug effects*
-
Candida / genetics
-
Caspofungin
-
Drug Resistance, Multiple, Fungal*
-
Echinocandins
-
Electrophoresis
-
Endocarditis / drug therapy
-
Endocarditis / microbiology*
-
Genotype
-
Heart Valve Prosthesis / microbiology*
-
Humans
-
Karyotyping
-
Lipopeptides
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Peptides, Cyclic / pharmacology*
-
Prosthesis-Related Infections / microbiology*
-
Recurrence
Substances
-
Antifungal Agents
-
Azoles
-
Echinocandins
-
Lipopeptides
-
Peptides, Cyclic
-
Caspofungin